Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect
Therapeutic Advances in Psychopharmacology · 2026-05 · 16
DOI: 10.1177/20451253261450772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 27.05.2026. Verfasst von Xiaoqian Lan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, Nat…. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Municipal Administration of Hospitals.
Abstract (Originalsprache)
Background
The potential of aripiprazole to reverse amisulpride-induced hyperprolactinemia has yet to be established.
Objectives
To investigate whether adjunctive aripiprazole treatment can reverse amisulpride-induced prolactin (PRL) elevation.
Design
This study was a single-arm retrospective cohort study.
Methods
We conducted a retrospective analysis of medical records from patients treated with amisulpride at a tertiary specialized psychiatric hospital, between June 1, 2022, and December 31, 2025, who subsequently received adjunctive aripiprazole. Data were collected via the electronic medical record system. A paired t -test was used to compare PRL values before (⩽7 days, PRL1) and after (⩾7 days, PRL2) aripiprazole initiation.
Results
The difference between PRL1 and PRL2 was not statistically significant (mean difference = 4.115 ng/ml, 95% CI (−5.121, 13.351) ng/ml, SD = 15.284, p = 0.351, Cohen’s d = 0.269, 95% CI for d (−0.290, 0.818)). Stratified analyses by sex and diagnosis yielded results consistent with the main analysis across subgroups ( p > 0.05). None of the leave-one-out analyses altered the study’s conclusions (all p -values > 0.05), indicating that the results were not driven by any single extreme value.
Conclusion
In individuals with amisulpride-related hyperprolactinemia, this retrospective study suggests that adjunctive aripiprazole has an insignificant therapeutic effect in reversing PRL elevation. Therefore, until more comprehensive research evidence becomes available, a cautious approach should be taken in clinical practice regarding the use of adjunctive aripiprazole to reverse amisulpride-induced PRL elevation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Me…
- Beijing Key Laboratory of Critical Bridging Technologies for Chronic Disease Drug Development.
- Beijing Key Laboratory of Critical Bridging Technologies for Chronic Disease Drug.
ORCID-Profile: Xiaoqian Lan
Förderung
- Beijing Municipal Administration of Hospitals
Zitieren
APA
Lan, X., Zhuang, H., & Li, P. (2026). Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261450772
Vancouver
Lan X, Zhuang H, Li P. Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261450772
BibTeX
@article{Lan2026,
author = {Lan, Xiaoqian and Zhuang, Hongyan and Li, Pengfei},
title = {Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect},
journal = {Therapeutic Advances in Psychopharmacology},
year = {2026},
volume = {16},
doi = {10.1177/20451253261450772}
}
EUVIMED